Erica Bazzell, APRN
Nurse Practitioner · Murray, KYNPI 1295070571
Payments from drug & device makers
Across 300 payments — averaging $13.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$567
- Pfizer$350
- Boehringer Ingelheim$284
- Lilly USA, LLC$231
- Amgen$190
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,88199%
- Education$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 76 | $1,042 |
| Novo Nordisk | 50 | $567 |
| Pfizer | 30 | $350 |
| Boehringer Ingelheim | 26 | $284 |
| Lilly USA, LLC | 13 | $231 |
| Amgen | 15 | $190 |
| Bayer | 12 | $175 |
| Novartis | 12 | $170 |
| Johnson & Johnson | 11 | $159 |
| Biohaven Pharmaceuticals, Inc. | 11 | $142 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $128 |
| Astellas Pharma US Inc | 6 | $85 |
| Merck | 5 | $73 |
| Sumitomo Pharma America, Inc. | 5 | $65 |
| Axsome Therapeutics, Inc. | 2 | $50 |
| AstraZeneca | 3 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Genentech USA, Inc. | 2 | $21 |
| Dexcom, Inc. | 1 | $20 |
| Exact Sciences | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| GSK | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Almatica Pharma LLC | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
| Endogastric Solutions, Inc | 1 | $9 |
How this compares
$3,940 in reported general payments places this provider in the 85th percentile of 1,918 nurse practitioner providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 79 | $83,951 |
| EliquisApixaban | 55 | $45,065 |
| XareltoRivaroxaban | 32 | $30,626 |
| FarxigaDapagliflozin Propanediol | 41 | $27,239 |
| MounjaroTirzepatide | 17 | $26,671 |
| JanuviaSitagliptin Phosphate | 12 | $18,921 |
| JardianceEmpagliflozin | 16 | $18,105 |
| EntrestoSacubitril/Valsartan | 18 | $12,336 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $12,220 |
| Repatha SureclickEvolocumab | 20 | $12,023 |
| Spiriva RespimatTiotropium Bromide | 22 | $11,353 |
| TrulicityDulaglutide | 13 | $10,585 |
| MultaqDronedarone Hcl | 11 | $9,403 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $9,207 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $6,994 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $567 | $83,95179 claims |
| PfizerEliquis | $350 | $45,06555 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat | $284 | $41,67764 claims |
| Lilly USA, LLCMounjaro, Trulicity | $231 | $37,25530 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $40 | $34,23353 claims |
| Johnson & JohnsonXarelto | $159 | $30,62632 claims |
| MerckJanuvia | $73 | $18,92112 claims |
| NovartisEntresto | $170 | $12,33618 claims |
| Sanofi-aventis U.S. LLCMultaq | $11 | $9,40311 claims |
| GSKTrelegy Ellipta | $13 | $9,20713 claims |
| AbbVieSynthroid | $1,042 | $2,78041 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,918 nurse practitioner providers in Kentucky.
Other nurse practitioner in Murray
- Rachael BradfordLexington$447K
- Tara MuddLouisville$243K
- Lee HaasLouisville$95K
- Ashley KnableLouisville$86K
- Christina BenningerLouisville$81K
- Courtney BowlingCampbellsville$47K
- Rebecca BraunerLouisville$40K
- Scott SeitzWinchester$34K
- Kristen KreinestEdgewood$34K
- Lillian ArgentEdgewood$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.